Tetrabenazine is the only drug approved by the US FDA for the treatment of chorea in Huntington’s disease (HD). Monitoring for adverse effects such as depressive symptoms and suicidal behavior is warranted, especially in patients with a history of depression.

In addition to a beneficial effect on chorea, olanzapine, risperidone, and tiapride also seem to have a positive effect on sleep dysfunction, mood disturbances, and the prevention of weight loss.

Potential dopamine-stabilizing and -depleting drugs to reduce motor symptoms in HD are currently under investigation in large multicenter clinical trials.